** Drug developer Dyne Therapeutics' DYN.O shares slide 14% to $19.09
** DYN late Monday kicked off public offering of $300 million worth of shares
** Stock closed up 9.5% on Monday after positive data for its muscle wasting drug
** Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are joint book-running managers for offering
** Proceeds will be used to repay debt and advance the development of its pipeline, among other purposes
** DYN has 142.6 million outstanding shares as of September 30, according to its prospectus
** 13 of 16 brokerages rate the stock "buy" or higher and three "hold"; median PT $38 - data compiled by LSEG
** As of last close, DYN stock was down 5.8% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com))
Comments